News
Apr 4, 2014
CardioCell to scout for CROs for PAD trial with allogeneic mesenchymal stem cells, in partnership talks – CEO
CardioCell will shop CROs for a Phase II trial in peripheral artery disease (PAD) for its IVadministered allogeneic ischemia-tolerant mesenchymal stem cells (itMSCs), according to CEO Sergey Sikora. SUBSCRIPTION REQUIRED TO READ FULL ARTICLE